Acumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on Thursday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Acumen Pharmaceuticals Price Performance

ABOS stock opened at $1.19 on Wednesday. Acumen Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $4.28. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The firm has a market capitalization of $71.50 million, a PE ratio of -0.86 and a beta of 0.02. The business has a 50 day simple moving average of $1.40 and a 200-day simple moving average of $2.01.

Insiders Place Their Bets

In other Acumen Pharmaceuticals news, CFO Matt Zuga sold 28,902 shares of the business’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $1.72, for a total value of $49,711.44. Following the transaction, the chief financial officer now directly owns 231,744 shares in the company, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Daniel Joseph Oconnell sold 47,778 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the sale, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at approximately $836,660.88. This trade represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 131,526 shares of company stock valued at $233,124. Insiders own 7.10% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.